Tissium Archives - M&L Group

Healthcare

TISSIUM Raises €50M in Series C Financing to Propel its Platform to Commercial Stage

31 August 2021 – PARIS, France TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for…

Natalie GoodridgeAugust 31, 2021

Healthcare

TISSIUM Selected for French Tech 120 Program

10 February 2021 – PARIS, France This is the second year TISSIUM has been included in…

Natalie GoodridgeFebruary 10, 2021

Healthcare

TISSIUM Adds to Executive Leadership Team

3 February 2021 – PARIS, France TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for…

Natalie GoodridgeFebruary 3, 2021

Healthcare

TISSIUM Announces Appointment of Independent Board Member

15 December 2020 TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced…

Natalie GoodridgeDecember 15, 2020

Healthcare

TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant

17 November 2020 IDE Approval Clears Path to U.S. Clinical Trial Launch for Vascular Sealant TISSIUM,…

Natalie GoodridgeNovember 17, 2020

Healthcare

TISSIUM Secures €7M State Guaranteed Loan

1 October 2020 – PARIS, France TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for…

Natalie GoodridgeOctober 1, 2020

Stick To The Plan – But Be Ready To Change

https://tissium.com/wp-content/uploads/2020/07/IV124510_TISSIUM_LRS_V3.pdf

30 Rising Leaders In The Life Sciences

https://insights.citeline.com/IV124494/30-Rising-Leaders-In-The-Life-Sciences/

How Investors Can Benefit From Borderless Healthcare Innovation

https://www.forbes.com/sites/lawrencelight/2020/04/26/how-investors-can-benefit-from-borderless-healthcare-innovation/?sh=35a309e04338

Innovative drug-eluting adhesives: Application in chronic rhinosinusitis

https://www.ondrugdelivery.com/innovative-drug-eluting-adhesives-application-in-chronic-rhinosinusitis/

Tissium

TISSIUM Raises €50M in Series C Financing to Propel its Platform to Commercial Stage

TISSIUM Selected for French Tech 120 Program

TISSIUM Adds to Executive Leadership Team

TISSIUM Announces Appointment of Independent Board Member

TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant

TISSIUM Secures €7M State Guaranteed Loan

Stick To The Plan – But Be Ready To Change

30 Rising Leaders In The Life Sciences

How Investors Can Benefit From Borderless Healthcare Innovation

Innovative drug-eluting adhesives: Application in chronic rhinosinusitis

M&L GROUP

We are a family investment firm that cultivates pioneering ventures into successful enterprises with passion, energy and integrity.

Hospitality

Healthcare

Shipping

Alternatives

Media room

About

Contact